Merck's Keytruda Gets Canadian Approval to Treat Muscle-Invasive Bladder Cancer

MT Newswires Live08-05 23:37

Merck (MRK) said Wednesday that Keytruda, in combination with enfortumab vedotin, has received Canadian approval for the treatment of muscle-invasive bladder cancer in adults who are ineligible for cisplatin-containing chemotherapy.

The company said that the approval from Health Canada was based on results from a phase-3 trial, which was conducted in collaboration with Pfizer (PFE) and Astellas.

Results from the trial showed that patients treated with neoadjuvant and adjuvant Keytruda in combination with enfortumab vedotin had statistically significant improvements in event-free survival and overall survival compared with radical cystectomy and pelvic lymph node dissection alone, the company said.

Price: 130.02, Change: +2.02, Percent Change: +1.58

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment